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Polymyxins are old antimicrobials, discontinued for many years because of nephrotoxicity and neurotoxicity reports and rein-
troduced recently due to the increasing frequency of multiresistant Gram-negative bacterial infections. There are very few data
related to toxicity and efficacy from transplanted patients, the major subjects of this study. All solid-organ-transplanted patients
from our institution during January 2001 to December 2007 who used polymyxins were retrospectively assessed for nephrotox-
icity and treatment efficacy. Microbiological and clinical cure rates were 100% and 77.2%, respectively. Only transplant patients
subjected to at least 72 h of intravenous polymyxin were entered in the study. Overall, 92 transplant patients were included, and
the nephrotoxicity rate was 32.6%. Multivariate analysis showed a statistically significant association between duration of poly-
myxin treatment (P 0.037; odds ratio [OR], 1.06; 95% confidence interval [CI], 1.00 to 1.12) and significant renal dysfunction.
Polymyxin use is associated with very high rates of significant decrease in renal function; therefore, polymyxin must be used only
when no other option is available and for as briefly as possible in the solid organ transplant setting.
Polymyxins are old antimicrobials, discovered in the 1940s (1),and their clinical use started in the late 1960s (2), acting
against Gram-negative bacteria such as Acinetobacter baumannii,
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia
coli (1). Nephrotoxicity and neurotoxicity reports (3–6) and the
development of new broad-spectrum and less toxic anti-Gram-
negative-organism agents such as cephalosporins and carbapen-
ems led to a brief discontinuation of polymyxin use. However,
since the 1990s, an increasing number of reports regarding the
emergence of multidrug-resistant Gram-negative bacteria, mainly
A. baumannii and P. aeruginosa, have been published (7). As a
result, polymyxins have reemerged as an alternative against such
multiresistant organisms.
Although recent studies have disclosed lower nephrotoxicity
rates than those in earlier reports, toxicity is still a major concern
and a reason for not employing this class of drugs (8, 9). Renal
transplant patients are more likely to develop renal toxicity by
different mechanisms (10), and renal dysfunction is adversely re-
lated to organ and recipient survival (11). On the other hand, due
to the severity of the patients’ conditions and the frequent use of
antimicrobials, Gram-negative bacterial multiresistance is a major
issue in hematopoietic stem cell transplantation and in solid organ
transplantation (12–14), showing the ever-increasing need for
polymyxin employment in this setting. Very few data regarding
polymyxin toxicity, especially nephrotoxicity, are available for
transplant patients. Our study aimed at analyzing nephrotoxicity
rates and the clinical and microbiological efficacy of polymyxin in
solid organ transplant patients.
MATERIALS AND METHODS
Objectives. The objectives of this study were to evaluate nephrotoxicity
rates and independent risk factors for nephrotoxicity in solid organ trans-
plant patients receiving polymyxin, as well as to describe the clinical and
laboratorial efficacy of this antimicrobial in this particular population.
Patients and methods. All medical records from solid organ trans-
plant patients were reviewed. Patients 18 years or older, who were treated
with polymyxin from January 2001 to December 2007 for at least 72 h and
with no need for dialysis for the first 48 h of treatment, were included.
This study was conducted in 2 university-affiliated-hospitals in São
Paulo, Brazil, Hospital São Paulo and Hospital do Rim e Hipertensão. The
former is a 700-bed general hospital, and the latter is a 100-bed hospital
specializing in renal transplantation.
The study was approved by the hospital ethics commission.
Demographic data.We reviewed demographic data for donors, recip-
ients, transplantation procedure, polymyxin use, nephrotoxic drug use 15
days before and/or during polymyxin use, renal function, and infection.
Main definitions. Infections were defined according to the clinical
judgment of assistant physicians as depicted in medical records. Basal
serum urea and creatinine were defined as urea and creatinine values
before polymyxin use. Multiresistant bacteria were defined as pathogens
that were resistant to carbapenems. Microbiologic cure was defined as
clearance in subsequent cultures of a pathogen initially isolated before
polymyxin use. Cure or clinical improvement was defined as total or par-
tial resolution of signs and symptoms of infection at the end of polymyxin
treatment. We considered death for any cause after 30 days of polymyxin
B use and total hospital mortality rate after polymyxin B use. Potentially
concomitant nephrotoxic drugs were vancomycin, amphotericin B, gan-
ciclovir, and calcineurin inhibitors. Polymyxin infusion time is the time
necessary for complete infusion in a single infusion.
Polymyxin dose and adjustment for renal correction (1). The poly-
myxin dose employed was 1.5 g to 2.5 g (1 g 10,000 IU) per kg of body
weight per day, and adjustment for renal function was as follows for poly-
myxin B: creatinine clearance (CLCR) of 80 ml/min, 1.5 to 2.5 mg/kg/
day; CLCR of 30 to 80 ml/min, loading dose of 2.5 mg/kg/day on the first
day and then 1.0 to 1.5 mg/kg/day; and CLCR of30 ml/min, loading dose
of 2.5 mg/kg/day on the first day and then 1.0 to 1.5 mg/kg/day every 2 to
3 days. For anuric patients, the loading dose was 2.5 mg/kg/day on the first
day and then 1.0 to 1.5 mg/kg/day every 5 to 7 days.
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Renal dysfunction criteria (15).The creatinine clearance rate was cal-
culated using the equation of Cockcroft and Gault (16). In patients with
normal renal function (serum creatinine level,1.2 mg/dl), renal failure
was defined as a serum creatinine value of2 mg/dl, as a reduction in the
calculated creatinine clearance of 50% relative to the value at antibiotic
therapy initiation, or as a decline in renal function that resulted in the
need for renal replacement therapy (i.e., intermittent hemodialysis or
continuous venovenous hemofiltration). In patients with preexisting re-
nal dysfunction, renal failure was defined as an increase of 50% over the
baseline creatinine level, as a reduction in the calculated creatinine clear-
ance of 50% relative to the value at antibiotic therapy initiation, or as a
decline in renal function that resulted in the need for renal replacement
therapy.
Microbiologic method. Antibiotic susceptibilities were determined
by disc diffusion and microdilution broth methods according to CLSI
(Clinical and Laboratory Standards Institute) standards.
Statistical analysis. For the evaluation of risk factors for polymyxin
nephrotoxicity, we compared groups with and without renal dysfunction
at any moment during polymyxin use according to renal dysfunction
criteria.
Univariate risk factor analysis for categorical variables was performed
using Pearson’s chi-square analysis (2), or Fisher’s exact test (FET) when
the supposition for 2 application was not satisfied. We performed the
Student t test for normal-distribution continuous variables, and we per-
formed the Mann-Whitney test for non-normal-distribution variables.
For multivariate analysis, the multiple nonconditional logistic regres-
sion model with stepwise variable selection to identify independent risk
factors was employed. All significant probabilities presented were bilateral
type, and values lower than 0.05 were considered statistically significant.
Statistical analysis of data was performed with SPSS software version 16.0
(Statistical Package for the Social Sciences software; Chicago, IL).
RESULTS
We retrospectively reviewed medical records from 94 solid organ
transplant patients who used polymyxin (polymyxins B and E)
according to study inclusion criteria. Two patients were excluded
because they needed dialysis within 48 h of polymyxin use. There-
fore, 92 patients were included in the final analysis. The majority
of the patients were renal transplants (83.7%), and 70.7% of them
received organs from deceased donors. The mean age was 47 
14.4 years (range, 20 to 72 years), and 57 patients were males
(62%), with a medium hospital stay length of 75.1 days (range, 3 to
889 days). Other demographic data are presented in Table 1. We
considered only the first polymyxin course of treatment (90 pa-
tients with polymyxin B and 2 patients with polymyxin E). Poly-
myxin B was used for a mean of 16.6 days (range, 3 to 46 days).
Mean and median polymyxin B doses employed were 922,282 and
1,000,000 IU/day, respectively. For statistical analysis related to
drug dose, time of infusion, and length of treatment, we consid-
ered only polymyxin B courses.
Of all infections, 83.7% were microbiologically confirmed. The
major type of infection was urinary tract infection (UTI) (41.3%),
followed by surgical site infection (SSI) (17.4%), pneumonia
(16.3%), primary bloodstream infection (5.4%), intra-abdominal
infection and soft tissue infection (2.2% each), and bloodstream
infection transmitted from the donor (1.1%); 8.7% of patients
were treated empirically with no source of infection detected. P.
aeruginosawas the main etiologic agent, at 76.1% of isolates; 5.4%
of isolates were A. baumannii, 1.1% each were K. pneumoniae and
Enterobacter sp., and for 16.3% of patients, the etiologic agent was
not recovered. Microbiological cure was observed in 25 patients
(100%) (24 urine cultures from recipients and one blood culture
from a donor, all of them kidney transplant patients), clinical cure
was observed in 71/92 patients (77.2%), and hospital mortality
occurred in 21/92 patients (22.8%) (Table 2).
Thirty patients (32.6%) developed nephrotoxicity; the mean
time for renal dysfunction development was 11 days (range, 3 to
TABLE 1 Demographic data for 92 solid organ transplant patients
treated with polymyxin
Variable
Mean or no.
of patients Range or %
Mean recipient age (yr) 47 20–72
Mean donor age (yr) 42 4–71
Mean total hospital stay (days) 75.1 3–889
Gender (male/female) 57/35 62/38
Location where polymyxin prescribed
Medical-surgical ward 77 83.7
ICU 15 16.3
Transplantation center
Hospital do Rim e Hipertensão 71 77.2
Hospital São Paulo 21 22.8
Organ(s) transplanted
Kidney 77 83.7
Kidney-pancreas 6 6.5
Liver 8 8.7
Heart 1 1.1
Immunosuppressant at time of
polymyxin use
79 85.9
Prednisone 69 75
Hydrocortisone 2 2.2
Dexamethasone 1 1.1
Tacrolimus 27 29.3
Mycophenolate mofetil 32 34.8
Azathioprine 10 10.9
Cyclosporine 27 29.3
Rapamycin 3 3.3
TABLE 2 Outcome and nephrotoxicity data for 92 solid organ
recipients who received polymyxin therapy
Variable
No. of patients
or mean % or range
Hospital mortality 21 22.8
30-day mortality 6 6.5
Microbiological cure 25a 100
Clinical cure 71 77.2
Graft loss in renal transplant 5 5.4
Acute pyelonephritis 1 1.1
Acute rejection 1 1.1
Chronic dysfunction 3 3.3
Mean serum creatinine level before
polymyxin (mg/dl)
2.22 0.7–9.6
Mean days to nephrotoxicity 11 3–24
Nephrotoxicity 30 32.6
Hemodialysis during therapy 15 16.3
a Data were available for 25 patients with a culture result before polymyxin use.
Twenty-four results were urine cultures, and for 1 patient, we examined a positive
donor blood culture that did not become positive in the recipient.
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24 days). Nephrotoxicity rates were 25%, 30%, and 51% on days 9,
16, and 29, respectively, after polymyxin was started (Fig. 1). Fif-
teen patients (16.3%) required dialysis during polymyxin treat-
ment. Graft loss after polymyxin use was recorded for five patients
(5.4%) (Table 2).
Using our criteria as the standard, by multivariate analysis, the
mean duration of polymyxin treatment (P  0.037; odds ratio
[OR], 1.06; 95% confidence interval [CI], 1.00 to 1.12) was inde-
pendently associated with renal failure (Table 3).
DISCUSSION
Recent studies suggest that polymyxin nephrotoxicity does not
occur at a level as high as was initially described and that the use of
polymyxin is safe with variable efficacy (15, 17–22). Although
Gram-negative bacterial resistance is common in the setting of
organ transplantation, little information on polymyxin use is
available for this group of patients (23, 24). Moreover, renal dys-
function is a frequent complication and may affect both patient
and graft survival (11).
Efficacy rates of polymyxin are variable and depend on the
study population. Michalopoulos et al. (25) demonstrated in a
series of 43 intensive care unit (ICU) hospitalized patients a clin-
ical cure rate of 69.8% and a microbiological cure rate of 67.4%.
Garnacho-Montero et al. (15), studying a cohort of 35 patients
using colistin or imipenem for treatment of A. baumannii venti-
lator-associated pneumonia (VAP), reported a clinical cure rate of
57% in both groups. In our study, we showed higher clinical
(77.2%) and microbiological (100%) cure rates. This may be ex-
plained by the higher frequency of patients with UTI diagnosis
than with VAP diagnosis, which was more frequent in the ICU
studies. Moreover, most of our patients were not critically ill, ren-
dering the comparison with a population of exclusively ICU pa-
tients not adequate. Nevertheless, polymyxin has been shown to
be very effective for UTI treatment, probably reflecting a high
concentration in urine (26–28).
Recent data regarding polymyxin pharmacokinetics/pharma-
codynamics in experimental and clinical studies suggest that the
dose traditionally used is probably insufficient, because of low
concentrations in plasma in critical patients (29–32). Some au-
thors suggest not adjusting for renal failure in any situation for
critical patients when using polymyxin B because of some evi-
dence that renal clearance of the drug is very low (32, 33). This
phenomenon may be leading to the emergence of strains resistant
to polymyxins (33).
Nephrotoxicity rates range from 8 to 45% (34–40), mainly in
critical care unit patients in recent studies. No data exclusively for
transplanted patients are available in such studies. Using the same
criteria, we found a high rate of nephrotoxicity (32.6%), although
the rate was lower than those in earlier studies (renal impairment
ranging from 20.2 to 36%) (3, 8, 9, 41, 42). A high proportion of
patients needed substitutive therapy during polymyxin use. This
rate of renal dysfunction is similar to rates described for drugs
being replaced by less toxic agents, such as amphotericin B. Bates
et al. (43), using the same toxicity score employed in our study and
reporting data on the treatment of 707 critically patients, reported
a renal dysfunction rate of 30% for deoxycholate-amphotericin B.
The high nephrotoxicity rate observed in our study overesti-
mates the toxic effect of polymyxin, since kidney transplant pa-
tients are prone to renal dysfunction. In fact, our patients had
initial mean creatinine levels in plasma of 2.22 mg/dl and 85.4%
had a serum creatinine level greater than or equal to 1 mg/dl at the
beginning of the study.
Multivariate analysis showed that the length of polymyxin use
is statistically associated with a worsening of renal function (P
0.037; OR, 1.06; 95% CI, 1.00 to 1.12). The medical literature
contains controversial data on this subject. Falagas et al. (17) in a
FIG 1 Survival free from nephrotoxicity in 92 solid organ transplant patients who received polymyxin therapy.
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prospective study of 21 patients who used at least 7 days of colistin
treatment showed a statistically significant correlation between
cumulative antibiotic dose and nephrotoxicity. The same author
in another publication (44) retrospectively evaluated 19 courses of
colistin for 4 weeks or more and showed that the average rise in
serum creatinine compared to baseline value after polymyxin E
use was only 0.25 mg/dl. Our study reinforces the hypothesis that
length of treatment and cumulative polymyxin use are related to
renal dysfunction in solid organ transplantation.
The diagnosis of UTI had a marginally protective effect in mul-
tivariate analysis. We regard it as a spurious association, since
patients with this diagnosis were less severely ill, based on a lower
rate of ICU admission than that of patients with other infections
(7.9% versus 59.3%, P 0.001).
The retrospective nature of the study imposes some limitations
regarding methodological aspects, mainly for diagnostic and mi-
crobiological characterization, and also for renal function moni-
toring. Since we did not have daily creatinine measurements for all
patients, the time to reach an endpoint for nephrotoxicity may be
underestimated. Serum urea and creatinine are not ideal markers
for renal function assessment, although they are reliable for com-
parison with literature data. Finally, the lack of a control group
and the analysis of a population subjected to multiple interven-
tions impacting renal function may overestimate the real nephro-
toxic effect of polymyxin.
Although we have disclosed a prohibitive rate of nephrotoxic-
ity related to polymyxin use in kidney transplant patients, we un-
derstand that for multidrug-resistant bacteria such as P. aerugi-
nosa and A. baumannii, polymyxin is sometimes the only viable
therapeutic alternative. We suggest, for the purpose of reducing
nephrotoxicity rates, using polymyxin judiciously only for true
infections (restricting, for instance, the treatment of asymptom-
atic bacteriuria and tracheal colonization) and for as brief a time as
possible.
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